替比夫定治疗妊娠晚期慢性乙型肝炎孕妇的临床观察

姜秀浓; 范玲燕; 李德周; 万炯; 叶菁菁

替比夫定治疗妊娠晚期慢性乙型肝炎孕妇的临床观察

宁波市第二医院肝炎四科

基金项目:

宁波市社会发展项目基金(2010C50034)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3734
- HTML全文浏览量: 16
- PDF下载量: 729
- 被引次数: 0
出版历程
- 出版日期: 2013-02-20

Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy

Research funding:

摘要

摘要:
目的研究慢性乙型肝炎孕妇妊娠晚期予替比夫定（LdT）抗病毒治疗对控制肝炎活动、阻断HBV母婴传播的意义。方法把116例HBsAg、HBeAg、抗-HBc阳性,HBV DNA≥1×105拷贝/ml,ALT≥2×ULN,伴或不伴TBil升高的慢性乙型肝炎孕妇,根据自愿原则分为两组,治疗组65例（孕28±2周）在护肝降酶的基础上服用LdT,600 mg/d,对照组51例仅予护肝降酶治疗,两组新生儿出生后均予主被动联合免疫。比较两组患者在分娩前及产后7个月HBV DNA、ALT、TBil水平的变化,比较两组新生儿在7个月时HBsAg携带率、抗-HBs阳转率,观察母婴并发症发生情况。结果治疗组孕妇分娩前及产后7个月HBV DNA、ALT、TBil值明显低于对照组,差异有统计学意义（P<0.05）;治疗组和对照组新生儿7个月时HBsAg携带率分别为1.5%和15.7%,抗-HBs阳性率分别为95.4%和78.4%,差异有统计学意义（P<0.05）。治疗组母婴并发症发生明显少于对照组。结论 LdT能有效控制肝炎活动,快速降低慢性乙型肝炎孕妇的HBV DNA水平,同时减少HBV母婴垂直传播...
- 替比夫定 /
- 肝炎,乙型,慢性 /
- 妊娠 /
- 疾病传播,垂直
Abstract:
Objective To investigate the significance of telbivudine (LdT) in controlling hepatitis activity and blocking mother-to-infant transmission of hepatitis B virus (HBV) in women with chronic hepatitis B (CHB) during late pregnancy.Methods A total of 116 pregnant women were enrolled.Each was positive for hepatitis B surface antigen (HBsAg) , hepatitis B e-antigen (HBeAg) and hepatitis B core antibody (anti-HBc) .They all also had HBV DNA levels of ≥105 copies/ml and alanine amino transferase (ALT) levels of ≥2×ULN, with or without total bilirubin (TBil) increase.They were divided into two groups based upon their personal preference, the treatment group (n=65) and control group (n=51) .The patients in the treatment group were (28±2) weeks pregnant and received LdT 600 mg once daily in addition to liver-protecting and enzyme-reducing treatments, while the patients in the control group received only the standard liver-protecting and enzyme-reducing treatment.All infants delivered by the participants received both active and passive immunization after birth.The women in the two groups were compared in terms of the HBV DNA, ALT and TBIL levels before delivery and at 7 months after delivery;positive rates of HBsAg and hepatitis B surface antibody (anti-HBs) were compared in the infants in both groups at 7 months after birth.Furthermore, maternal and neonatal complications were observed.Results The levels of serum HBV DNA, ALT and TBIL in the treatment group were significantly lower than those in the control group before delivery and at 7 months after delivery (P<0.05) .At 7 months after birth, the infants in the treatment group had a significantly lower positive rate for HBsAg (1.5% vs.15.7%, P<0.05) and a significantly higher anti-HBs-positive rate (95.4% vs.78.4%, P<0.05) compared with those in the control group.Maternal and neonatal complications occurred significantly less frequently in the treatment group than in the control group.Conclusion LdT is effective in controlling hepatitis activity in pregnant women with CHB, as it rapidly decreases HBV DNA levels and reduces mother-to-infant transmission of HBV.Its use is therefore beneficial to both mothers and infants.
- telbivudine /
- hepatitis B /
- chronic /
- pregnancy

HTML全文

参考文献(10)

[1]Swat S, Manoj K.Pregnancy and chronic hepatitis B virus in-fection[J].Hepatol Res, 2010, 40 (1) :31-48.

[2] Hoofnagle JH, Doo E, Liang TJ, et al.Management of hep-atitis B:summary of a clinical researchworkshop[J].Hepa-tology, 2007, 45 (4) :1056-1075.

[3] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association.The Guidelineof Prevention and Treatment for Chronic Hepatitis B (2010Version) [J].Chin J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会、中华医学会感染病分会, 慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[4]Han GR, Cao MK, Zhao W, et al.A prospective and open-label study for the efficacy and safety of telbivudine in preg-nancy for the prevention of perinatal transmission of hepatitisB virus infection[J].J Hepatol, 2011, 55 (6) :1215-1221.

[5]刘克洲, 陈智.人类病毒性疾病[M].北京:人民卫生出版社, 2002:503-504.

[6]Chatterjee S, Ravishankar K, Chatterjee R, et al.Hepatits Bprevalence during pregnany[J].Indian Pediatr, 2009, 46 (11) :1005-1008.

[7]Sinha S, Kumar M.Pregnancy and chronic hepatitis B virusinfection[J].Hepatol Res, 2010, 40 (1) :31-48.

[8] Han GR, Jiang HX, Wang GJ, et al.Efficacy and safety ofteibivudine in pregnant women to prevent perinatai transmis-sion of hepatitis B virus[J].Chin J Hepatol, 2012, 20 (3) :201-205. (in Chinese) 韩国荣, 江红秀, 王根菊, 等.替比夫定乙型肝炎病毒高载量孕妇母婴传播的阻断效果及其安全性[J].中华肝脏病杂志, 2012, 20 (3) :201-205.

[9]Chen XQ, Yao ZC, Wu LP, et al.Clinical study on telbivudi-ne in preventing mother-to-infant HBV transmission dur-ing the late pregnancy[J].Chin J Clin Hepatol, 2011, 27 (12) :1282-1284. (in Chinese) 陈晓勤, 姚展成, 吴丽萍, 等.妊娠晚期应用替比夫定阻断乙型肝炎病毒垂直传播的临床观察[J].临床肝胆病杂志, 2011, 27 (12) :1282-1284.

[10]Bridges EG, Selden JR, Luo S.Nonclinical safety profile oftelbivudine, a novel potent antiviral agent for treatment ofhepatitis B[J].Antimicrob Agents Chemother, 2008, 52 (7) :2521-2528.

施引文献

资源附件(0)

访问统计